Showing results (271-280 of 364) with videos related to
Sort By:
Pageof 37
Nature Communications|March 16, 2022
Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genesIndu Kohaar, Xijun Zhang, Shyh-Han Tan, et al.BMC Cancer|September 7, 2020
Bayesian copy number detection and association in large-scale studiesStephen Cristiano, David McKean, Jacob Carey, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2017
Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical TrialChanning J Paller, Xian C Zhou, Elisabeth I Heath, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 17, 2018
Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related DonorsHany Elmariah, Yvette L Kasamon, Marianna Zahurak, et al.Scientific Reports|July 24, 2021
Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasiaMichael A Kiebish, Poornima Tekumalla, Shobha Ravipaty, et al.Blood|October 16, 2014
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDSChristopher G Kanakry, Hua-Ling Tsai, Javier Bolaños-Meade, et al.Haematologica|November 16, 2016
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideShannon R McCurdy, Yvette L Kasamon, Christopher G Kanakry, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2015
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older AdultsYvette L Kasamon, Javier Bolaños-Meade, Gabrielle T Prince, et al.Blood|March 28, 2015
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R McCurdy, Jennifer A Kanakry, Margaret M Showel, et al.JCO Precision Oncology|August 11, 2022
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint InhibitorsDiana Merino Vega, Katherine K Nishimura, Névine Zariffa, et al.Pageof 37